In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK ‐875-Reference-Cited by-同舟云学术

In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK ‐875

Published:2020-05-02 Issue:6 Volume:81 Page:708-715
ISSN:0272-4391
Container-title:Drug Development Research
language:en
Short-container-title:Drug Dev Res

Author:

Yan Yugang¹²,Xu Qifu¹,Zhao Chunlong¹,Dong Hang¹,Xu Wenfang¹,Zhang Yingjie¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education)School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University Ji'nan China

2. School of Medical Engineering, Jining Medical University Jining China

Funder

Key Technology Research and Development Program of Shandong

Natural Science Foundation of Shandong Province

Publisher

Wiley

Subject

Drug Discovery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.21675

Reference27 articles.

1. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes

2. The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids

3. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes

4. Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties

5. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sulfones of Pyridinyloxy-Substituted Imidazo[2,1-b][1,3]thiazines: Synthesis, Anti-Inflammatory Activity Evaluation In Vivo and Docking Studies;Letters in Drug Design & Discovery;2022-08-12

2. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity;Bioorganic & Medicinal Chemistry Letters;2021-06